23 May 2016InDex Pharmaceuticals receives grant from Sweden´s innovation agency Vinnova for pre-clinical development of DIMS compounds in inflammation
InDex Pharmaceuticals AB today announced it has been granted 1.825 million SEK from Sweden´s innovation agency Vinnova to develop new, more effective and safer treatments for inflammatory diseases. Of 535 applications and 84 funded projects, InDex received one of the largest grants.
18 May 2016
Wilson Therapeutics AB (publ), announces that the company's ongoing Phase II clinical trial evaluating the safety and efficacy of Decuprate® (bis-choline tetrathiomolybdate; WTX101) in Wilson Disease patients has been fully enrolled.
16 May 20164Tech and Dr. Jean-Claude Laborde enter into partnership to accelerate 4Tech R&D and clinical development
4Tech Inc., which is developing the world’s first transcatheter device, TriCinch ™ , for repair of the Tricuspid heart valve, today announced its partnership with Dr. Jean-Claude Laborde as an R&D and clinical advisor focused on fast-forwarding the TriCinch™ Generation Two and Generation Three programs.
16 May 2016
TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory diseases of the gastrointestinal tract and eye, announces that it has completed the preclinical development of TOP1630 for the treatment of dry eye disease. An investigational new drug (IND) application is being prepared for submission later in the year ahead of a planned Phase I/II study in the US which is on track to commence in early 2017.
12 May 2016